| P50 | author | Karl-Friedrich Becker | Q40017441 |
| | Rupert Langer | Q56422424 |
| P2093 | author name string | Axel Walch | |
| | Julia Slotta-Huspenina | |
| | Marcus Feith | |
| P2860 | cites work | A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas | Q37040615 |
| | The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 |
| | Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes | Q37554911 |
| | Inhibiting HSP90 to treat cancer: a strategy in evolution | Q38026904 |
| | Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. | Q38030442 |
| | Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers | Q39448675 |
| | A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. | Q40040751 |
| | Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo | Q40158485 |
| | HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. | Q45387477 |
| | Characterization of signalling pathways by reverse phase protein arrays | Q47863761 |
| | Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. | Q54594739 |
| | Hsp90 Recognizes a Common Surface on Client Kinases | Q58008219 |
| | Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues | Q60056797 |
| | Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers | Q27022514 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | HER2 testing in gastric cancer: a practical approach | Q28256814 |
| | Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas | Q28728855 |
| | Discovery of new molecular subtypes in oesophageal adenocarcinoma | Q28744610 |
| | The heat-shock proteins | Q29617227 |
| | HSP90 and the chaperoning of cancer | Q29617504 |
| | Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus | Q33323234 |
| | Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications | Q33899708 |
| | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature | Q34223664 |
| | Heat shock proteins in cancer: chaperones of tumorigenesis | Q34495261 |
| | Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 |
| | Inhibition of HSP90 molecular chaperones: moving into the clinic | Q34654791 |
| | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | Q34852929 |
| | Hsp90 molecular chaperone inhibitors: are we there yet? | Q35655105 |
| | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 |
| | Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment | Q35800838 |
| | Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs | Q35823157 |
| | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma | Q36910400 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 1382-1393 | |
| P577 | publication date | 2014-06-27 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus | |
| P478 | volume | 6 | |